Acoramidis hydrochloride is under clinical development by BridgeBio Pharma and currently in Pre-Registration for Familial Amyloid Cardiomyopathy. According to GlobalData, Pre-Registration drugs for Familial Amyloid Cardiomyopathy have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Acoramidis hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Acoramidis hydrochloride overview

BBP-265 (AG-10) is under development for the treatment of familial amyloid cardiomyopathy (ATTR-CM). The drug candidate is administered through oral route in the form of tablet. It acts by targeting transthyretin protein.

It was under development for the treatment of familial amyloid polyneuropathy (FAP/hereditary transthyretin amyloidosis) and amyloidosis.

BridgeBio Pharma overview

BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company that develops drugs for genetic diseases and cancer. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its precision cardiorenal and mendelian drugs include acoramidis, encaleret, fosdenopterin, low-dose infigratinib, BBP-418 and BBP-671. BridgeBio’s precision oncology and gene therapy drugs include high-dose infigratinib, BBO-8520, BBP-398, PI3Ka, BBP-954, Pan-KRAS inhibitor, BBP-812, BBP-631 and AAV gene therapy. The company’s brands include TRUSELTIQ and NULIBRY. It works in partnership with academic partners and industrial partners. The company operates in Canada, the US, France, Germany, Switzerland and the UK, among others. BridgeBio is headquartered in Palo Alto, California, the US.

For a complete picture of Acoramidis hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.